New consumer longevity brand to support company’s clinical development of therapeutics based on proprietary resveratrol delivery platform.
Clinical stage biotech Jupiter Neurosciences has officially launched a new line of consumer supplements designed to support health and performance, broadening its focus from clinical-stage pharmaceuticals into the consumer longevity market. The company is leveraging its proprietary micellar resveratrol delivery technology to the nutraceutical space, offering a range of supplements designed to enhance healthspan, cognitive clarity and metabolic resilience.
The new supplement brand, called Nugevia, emerges from Jupiter’s primary focus on optimizing the therapeutic delivery of resveratrol to target neuroinflammation and combat neurodegenerative diseases. Resveratrol, a compound long recognized for its potential antiaging and anti-inflammatory effects, has been limited in its clinical utility due to poor bioavailability and adverse gastrointestinal effects at higher doses. Jupiter claims its proprietary platform, JOTROL, addresses these limitations through a micellar formulation that improves absorption while maintaining a strong safety profile. In clinical studies, the company says JOTROL demonstrated a ninefold increase in bioavailability without the gastrointestinal side effects typically associated with high-dose resveratrol.
“The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,” said Jupiter CEO Christer Rosén. “By building on the same proprietary technology platform that underpins our prescription drug development, we’re delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.”
The first three formulations – focused on mitochondrial function, cognitive enhancement and internal wellness – are set to launch through a direct-to-consumer model in the third quarter of 2025. The supplements incorporate JOTROL as a core ingredient and blend resveratrol with other synergistic compounds, using an “intelligent stacking” strategy intended to promote cellular health, optimize delivery across the blood-brain barrier and support holistic performance.
After raising $11 million in its IPO last December, the commercial expansion also creates a financial engine to support Jupiter’s ongoing clinical development efforts. The company’s lead pharmaceutical program, focused on the treatment of central nervous system disorders, is progressing toward a Phase 2a clinical trial in Parkinson’s following positive Phase 1 safety results.
“Nugevia represents more than a product launch – it’s a strategic engine for growth,” said Rosén. “By leveraging our core science in a consumer format, we’re creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It’s smart capital allocation with real scientific impact.”
